Pasquale Morese
Ayaz Ahmad
Dr Mathew Martin
Dr Richard Noble
Sara Pintar
et al. | Factors affecting irreversible inhibition of EGFR and influence of chirality on covalent binding | 2025 |
|
Duncan Miller
Dr Suzannah Harnor
Dr Mathew Martin
Dr Richard Noble
Professor Steve Wedge
et al. | Modulation of ERK5 Activity as a Therapeutic Anti-Cancer Strategy | 2023 |
|
Dr Nahoum Anthony
Charlotte Jennings
Dr Mathew Martin
Dr Richard Noble
Nicole Phillips
et al. | Targeting cytotoxic agents through EGFR-mediated covalent binding and release | 2023 |
|
Duncan Miller
Tristan Reuillon
Dr Lauren Molyneux
Dr Tim Blackburn
Dr Noel Edwards
et al. | Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor | 2022 |
|
Dr Richard Noble
Huw Thomas
Dr Yan Zhao
Professor Steve Wedge
| Simultaneous targeting of glycolysis and oxidative phosphorylation as a therapeutic strategy to treat diffuse large B-cell lymphoma | 2022 |
|
Honorine Lebraud
Dr Richard Noble
Nicole Phillips
Dr Yan Zhao
Professor Herbie Newell
et al. | A highly potent clickable probe for cellular imaging of MDM2 and assessing dynamic responses to MDM2-p53 inhibition | 2018 |
|
Dr Richard Noble
Dr Natalie Bell
Dr Helen Blair
Huw Thomas
Nicole Phillips
et al. | Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and burkitt lymphoma | 2017 |
|
